ArticleClinical ophthalmology (Auckland, N.Z.)2026
PAIR: Evaluating the Limits of Agreement Among Non-Retinal Specialist Using PathFinder Artificial Intelligence Tool for Retinal Disease Referrals: A Prospective Observational Study.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AI-Assisted Detection of Macular OCT Abnormalities by Optometrists: A Retrospective Reader Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- The AI-Augmented Ophthalmologist for chronic ocular diseases: a patient-centered framework for human-AI collaboration.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the diagnostic and referral agreement between non-retina specialists (NRS) using the PathFinder artificial intelligence (AI) assistant and fellowship-trained retina specialists Methods: This cross-sectional study included 202 consecutive patients undergoing OCT on the CIRRUS platform with the PathFinder AI module. Three Results: Among 202 eyes (mean age 62.7 ± 12.3 years), Conclusion: PathFinder is a valuable real-time decision-support tool in resource-limited settings; however, disease-specific refinements and clinical oversight remain important, particularly for vision-threatening conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.